Skip to content
TickerMagic

Thyrocare Technologies Limited

THYROCARENSEHealthcare
₹504.85
+1.25 (+0.25%) · EOD 2026-11-20

Our verdict

Hold

Quality (93/100) does the heavy lifting; valuation (16/100) is the drag.

ExpensiveHealth AOvervalued
Quality 93Momentum 34Value 16Trend 90The Spark ↓

Our fair value

Overvalued by 38%
₹315.15down 37.58%
Price ₹505Range ₹252 – ₹414

Buy-below (20% margin of safety): ₹252.12

The bottom line

Thyrocare Technologies Limited earns a Hold from TickerMagic, with a blended score of 45/100. At ₹504.85 it trades above our blended DCF and relative-multiples fair value of ₹315.15, about 38% downside to that estimate — we read it as overvalued by 38%. On 51.2x trailing earnings it sits pricier than the Healthcare median of about 37.4x. The price is about 22% below its 52-week high of ₹649.35 and 46% above the low of ₹345.06. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 8/9. The average analyst target of ₹603 implies about 19% upside across 5 analysts. It clears 10 of 13 investability checks, with durability 93, valuation 32 and momentum 34 on our 0–100 scales.

Analysis by Ankit Sharma · TickerMagic's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.

Intrinsic value
Our fair value
₹315.15down 37.58%
Overvalued by 38%
Price ₹504.85Range ₹252.43–₹413.74
DCF + relative blendhigh confidence

With a 20% margin of safety, our buy-below price is ₹252.12.

Analyst views

5 analysts5 buy · 0 hold · 0 sell
12-month consensus target₹603up 19.44%

1-year price

EOD · 2026-11-20
1D
up 0.25%
1W
up 3.45%
1M
up 7.19%
3M
down 17.00%
6M
up 8.66%
1Y
—

52-week range

-22.25% from the 52-week high.

Trend check
Below 50-DMA₹516Above 200-DMA₹486

Price above both moving averages reads as an intact uptrend; below both, the trend is against you.

Verdict pillars

Hold45
A
Financial health 100/100
Altman Z 35.21 · Safe zone

Piotroski F-score 8/9 — quality of earnings & balance sheet.

Our scores

Durability93
Valuation32
Momentum34

Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.

Investability checklist

Passed 10 of 13 checks
Each check screens one fundamentals, valuation or trend signal.
  • Pass: ROE above 15%: 28.7%
  • Pass: Low debt (D/E < 0.5): 0.09x
  • Pass: Positive free cash flow
  • Pass: Revenue growth > 10%: 20%
  • Pass: Earnings growing: 116%
  • Pass: Net margin ≥ 10%: 19.7%
  • Pass: Current ratio > 1.5: 3.39
  • Fail: Below our fair value
  • Fail: Margin of safety ≥ 20%
  • Pass: Above 200-day average
  • Fail: Above 50-day average
  • No data: Positive 1-year return
  • Pass: Altman Z in safe zone: Z 35.21
  • Pass: Piotroski ≥ 7: 8/9

Quarterly results

Revenue · 2Q2026
₹240 Cr
Net profit
₹52 Cr
Margin
22%
4Q2025
1Q2026
2Q2026
Revenue Net profitLatest revenue QoQ +7%

Annual financials

Revenue · 2026
₹822 Cr
Net profit
₹163 Cr
Margin
20%
2023
2024
2025
2026
Revenue Net profitLatest revenue YoY +21%

Shareholding

  • Promoter61.1%
  • Institutions21.5%
  • Public & other17.4%

Promoter holding via insider stake; institutional via reported holdings.

Key fundamentals

Market cap
₹8,981 Cr
P/E ratio
51.2
P/B ratio
15.34
EPS (TTM)
₹11.01
ROE
28.7%
Debt / Equity
0.09x
Profit margin
19.7%
Free cash flow
₹172 Cr
52-week high
₹649.35
-22.25% from high
52-week low
₹345.06
Dividend yield
2.9%
Beta
0.47
SWOT snapshot

Bull case vs bear case

Bull case

Strengths

  • Strong return on equity (28.7%).
  • Lightly leveraged balance sheet.
  • Healthy profit margin (19.7%).
  • Financially solid — Altman Z 35.21.
  • High Piotroski quality score (8/9).

Opportunities

  • Earnings growing (116% YoY).
  • Revenue growing (20% YoY).

Bear case

Threats

  • Trades ~38% above our estimated fair value.

About Thyrocare Technologies Limited

Thyrocare Technologies Limited operates diagnostic testing services across India through three segments: Diagnostic Testing Services, Imaging Services, and Others. The Diagnostic Testing Services segment sells consumables for specimen collection and promotes pathology services to patients, laboratories, and hospitals.

Thyrocare Technologies Limited — frequently asked questions

Is Thyrocare Technologies Limited a buy, hold or sell?

TickerMagic currently rates Thyrocare Technologies Limited (THYROCARE) a Hold, based on a blended score of 45/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.

What is Thyrocare Technologies Limited's fair value?

Our blended DCF and relative-valuation model estimates Thyrocare Technologies Limited's fair value at about ₹315.15, versus a current price of ₹504.85 — roughly 38% downside. On that basis the stock looks overvalued by 38%.

Is Thyrocare Technologies Limited financially healthy?

Thyrocare Technologies Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 8/9.

How has Thyrocare Technologies Limited's share price performed?

Thyrocare Technologies Limited is down 17% over three months, and last traded at ₹504.85. Past performance doesn't predict future returns.

Our verdict, fair value, financial-health and checklist are TickerMagic's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.